<DOC>
	<DOCNO>NCT02021643</DOCNO>
	<brief_summary>This study evaluate safety efficacy sofosbuvir+ribavirin ( RBV ) , +/- pegylated interferon , treatment-naive treatment-experienced adult chronic genotype 1 , 2 , 3 6 HCV infection . The study conduct China , Hong Kong ( HK ) , Korea , Taiwan , Vietnam . Participants enrol study 12 , 16 , 24 week treatment .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir Plus Ribavirin Subjects With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA â‰¥ 10^4 IU/mL screen HCV treatmentnaive ( HCV genotype 1 , 2 , 3 6 ) , define prior exposure interferon ( IFN ) , RBV , approve experimental HCVspecific directacting antiviral agent , HCV treatmentexperienced ( HCV genotype 1 , 2 , 3 , 6 ) medical record include sufficient detail prior treatment IFN allow categorization prior response either IFN Intolerant , nonresponder , experience viral breakthrough relapse HCV infection document antiHCV antibody test , genotyping test , liver biopsy Key Current prior history clinicallysignificant illness ( HCV ) Pregnant nurse female male pregnant female partner Chronic liver disease nonHCV etiology Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>